CLNN Clene Inc. Forecast, Technical & Fundamental Analysis
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics... Show more
CLNN is expected to report earnings to fall 52.42% to -32 cents per share on August 17
Q2'26
Est.
$-0.33
Q1'26
Missed
by $0.23
Q4'25
Missed
by $0.78
Q3'25
Missed
by $0.78
Q2'25
Missed
by $0.71
The last earnings report on May 14 showed earnings per share of -68 cents, missing the estimate of -46 cents. With 11.62K shares outstanding, the current market capitalization sits at 75.78M.
A.I. Advisor
published General Information
General Information
a blank check company, which was created with purpose to acquire, engage in a share exchange, share reconstruct, amalgate, and purchase all substantially all of the assets of, entering into contractual arrangements
A.I.dvisor indicates that over the last year, CLNN has been loosely correlated with KYMR. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if CLNN jumps, then KYMR could also see price increases.
CLNN's RSI Oscillator ascends from oversold territory
The RSI Oscillator for CLNN moved out of oversold territory on June 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 43 similar instances when the indicator left oversold territory. In of the 43 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 17, 2026. You may want to consider a long position or call options on CLNN as a result. In of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for CLNN just turned positive on June 18, 2026. Looking at past instances where CLNN's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CLNN advanced for three days, in of 231 cases, the price rose further within the following month. The odds of a continued upward trend are .
CLNN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
CLNN moved below its 50-day moving average on June 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CLNN crossed bearishly below the 50-day moving average on June 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLNN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for CLNN entered a downward trend on June 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CLNN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.025) is normal, around the industry mean (4.722). P/E Ratio (0.000) is within average values for comparable stocks, (34.858). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.836). CLNN has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.063). CLNN's P/S Ratio (476.190) is very high in comparison to the industry average of (8.642).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLNN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
